194 related articles for article (PubMed ID: 11076265)
21. Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera.
Kremyanskaya M; Mascarenhas J; Hoffman R
Expert Opin Pharmacother; 2015 Jun; 16(8):1185-94. PubMed ID: 25873215
[TBL] [Abstract][Full Text] [Related]
22. The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981.
Najean Y; Rain JD
Semin Hematol; 1997 Jan; 34(1):6-16. PubMed ID: 9025157
[No Abstract] [Full Text] [Related]
23. The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera.
Heis N; Rintelen C; Gisslinger B; Knöbl P; Lechner K; Gisslinger H
Eur J Haematol; 1999 Jan; 62(1):27-31. PubMed ID: 9918308
[TBL] [Abstract][Full Text] [Related]
24. Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period.
West WO
South Med J; 1987 Mar; 80(3):323-7. PubMed ID: 3824016
[TBL] [Abstract][Full Text] [Related]
25. New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera.
Tefferi A; Barbui T
Am J Hematol; 2015 Aug; 90(8):683-5. PubMed ID: 25872987
[No Abstract] [Full Text] [Related]
26. Acute leukemia in polycythemia vera.
Landaw SA
Semin Hematol; 1986 Apr; 23(2):156-65. PubMed ID: 3704667
[No Abstract] [Full Text] [Related]
27. Treatment outcome in a cohort of young patients with polycythemia vera.
Ruggeri M; Finotto S; Fortuna S; Rodeghiero F
Intern Emerg Med; 2010 Oct; 5(5):411-3. PubMed ID: 20607450
[TBL] [Abstract][Full Text] [Related]
28. Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.
Passamonti F; Cazzola M
Haematologica; 2004 Nov; 89(11):1284. PubMed ID: 15531447
[No Abstract] [Full Text] [Related]
29. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
30. Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia.
Brusamolino E; Salvaneschi L; Canevari A; Bernasconi C
J Clin Oncol; 1984 Jun; 2(6):558-61. PubMed ID: 6374054
[TBL] [Abstract][Full Text] [Related]
31. [Polycythemia vera--focus on the Hb value. Future treatment can maybe result in disease remission].
Johansson P; Andreasson B; Samuelsson J
Lakartidningen; 2009 Jan 14-20; 106(3):104-9. PubMed ID: 19248459
[No Abstract] [Full Text] [Related]
32. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
Alvarez-Larrán A; Pérez-Encinas M; Ferrer-Marín F; Hernández-Boluda JC; Ramírez MJ; Martínez-López J; Magro E; Cruz Y; Mata MI; Aragües P; Fox ML; Cuevas B; Montesdeoca S; Hernández-Rivas JA; García-Gutiérrez V; Gómez-Casares MT; Steegmann JL; Durán MA; Gómez M; Kerguelen A; Bárez A; García MC; Boqué C; Raya JM; Martínez C; Albors M; García F; Burgaleta C; Besses C;
Haematologica; 2017 Jan; 102(1):103-109. PubMed ID: 27686377
[TBL] [Abstract][Full Text] [Related]
33. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
34. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
Kiladjian JJ; Chevret S; Dosquet C; Chomienne C; Rain JD
J Clin Oncol; 2011 Oct; 29(29):3907-13. PubMed ID: 21911721
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular events and intensity of treatment in polycythemia vera.
Marchioli R; Finazzi G; Specchia G; Cacciola R; Cavazzina R; Cilloni D; De Stefano V; Elli E; Iurlo A; Latagliata R; Lunghi F; Lunghi M; Marfisi RM; Musto P; Masciulli A; Musolino C; Cascavilla N; Quarta G; Randi ML; Rapezzi D; Ruggeri M; Rumi E; Scortechini AR; Santini S; Scarano M; Siragusa S; Spadea A; Tieghi A; Angelucci E; Visani G; Vannucchi AM; Barbui T;
N Engl J Med; 2013 Jan; 368(1):22-33. PubMed ID: 23216616
[TBL] [Abstract][Full Text] [Related]
36. [True polycythemia: current views of pathogenesis, diagnostics and treatment].
Vatutin NT; Taradin GG; Bakhteeva TD; Kalinkina NV; Skliannaia EV
Klin Med (Mosk); 2012; 90(8):24-31. PubMed ID: 23101255
[TBL] [Abstract][Full Text] [Related]
37. Natural history and management of polycythemia vera.
Hoffman R; Wasserman LR
Adv Intern Med; 1979; 24():255-85. PubMed ID: 371361
[No Abstract] [Full Text] [Related]
38. Polycythemia vera.
Hematol Oncol Clin North Am; 2003 Oct; 17(5):1191-210. PubMed ID: 14560782
[TBL] [Abstract][Full Text] [Related]
39. A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera.
Sacchi S; Leoni P; Liberati M; Riccardi A; Tabilio A; Tartoni P; Messora C; Vecchi A; Bensi L; Rupoli S
Ann Hematol; 1994 May; 68(5):247-50. PubMed ID: 8018766
[TBL] [Abstract][Full Text] [Related]
40. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients.
Chistolini A; Mazzucconi MG; Ferrari A; la Verde G; Ferrazza G; Dragoni F; Vitale A; Arcieri R; Mandelli F
Haematologica; 1990; 75(6):537-40. PubMed ID: 2098295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
